Shares of Illumina (ILMN), a leading genomics company, soared 6.16% in pre-market trading on Friday, following the release of its impressive third-quarter results, raised full-year guidance, and a series of analyst upgrades. The company's performance significantly exceeded expectations, demonstrating strong growth in key areas and improved financial metrics.

Illumina reported Q3 revenue of $1.084 billion, surpassing the analyst consensus estimate of $1.065 billion. The company's adjusted earnings per share (EPS) came in at $1.34, handily beating the expected $1.17. This represents a substantial 17.54% increase from the $1.14 per share reported in the same period last year. Additionally, Illumina's adjusted net income of $206 million outperformed analyst projections of $182.2 million.

The robust quarterly performance was primarily driven by growth in the clinical market, Illumina's largest segment, as highlighted by CEO Jacob Thaysen. The company also reported a return to growth outside of China, indicating successful execution of its strategic initiatives aimed at achieving long-term targets. In a show of confidence, Illumina raised its fiscal year 2025 guidance, further fueling investor optimism. The company now expects non-GAAP EPS in the range of $4.65 to $4.75, up from its previous estimate of $4.45 to $4.55.

Following the strong results and improved outlook, several analysts raised their target prices for Illumina stock. Jefferies increased its target from $100 to $108, while Canaccord Genuity raised its target to $112 from $105. JP Morgan and TD Cowen also boosted their targets to $105 and $115, respectively. These upgrades reflect growing confidence in Illumina's ability to navigate challenges and capitalize on growth opportunities in the genomics sector. As the company continues to innovate and expand its market presence, investors will be closely watching for sustained momentum in the coming quarters.